Purification process
    3.
    发明授权
    Purification process 失效
    净化过程

    公开(公告)号:US06313289B1

    公开(公告)日:2001-11-06

    申请号:US09341542

    申请日:1999-08-04

    IPC分类号: C07D50104

    CPC分类号: C07D501/00

    摘要: Crystalline 2-(amninothiazol-4-yl)-2-(tert.butoxycarbonylmethoxyimino)acetic acid-S-mercapto-benzo-thiazolylester in form of an N,N-dimethylacetamide solvate; a crystalline salt of a 7-[2-(aminothiazol-4-yl)-2-(carboxymethoxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid with an amine of formula N(R1)(R2)(R3), wherein R1, R2, and R3 have various meanings, a crystalline sulphuric acid addition salt of a 7-[2-(2-aminothiazol-4-yl)-2-carboxymethoxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid; and the use of these salts in the production of cefixime, e.g. in form of a trihydrate.

    摘要翻译: N,N-二甲基乙酰胺溶剂化物形式的2-(氨基噻唑-4-基)-2-(叔丁氧基羰基甲氧基亚氨基)乙酸S-巯基 - 苯并噻唑酯的结晶; 7- [2-(氨基噻唑-4-基)-2-(羧基甲氧基亚氨基)乙酰氨基] -3-乙烯基-3-头孢烯-4-羧酸与式N(R1)(R2)的胺的结晶盐, (R3),其中R1,R2和R3具有各种含义,7- [2-(2-氨基噻唑-4-基)-2-羧甲氧基亚氨基)乙酰氨基] -3-乙烯基-3 - 头孢-4-羧酸; 以及这些盐在头孢克肟的生产中的用途。 呈三水合物的形式。

    CRYSTALLINE FORM C OF TIGECYCLINE DIHYDROCHLORIDE AND METHODS FOR ITS PREPARATION
    4.
    发明申请
    CRYSTALLINE FORM C OF TIGECYCLINE DIHYDROCHLORIDE AND METHODS FOR ITS PREPARATION 有权
    二乙基二氯化锆的结晶形式及其制备方法

    公开(公告)号:US20120022025A1

    公开(公告)日:2012-01-26

    申请号:US13133164

    申请日:2009-12-18

    CPC分类号: C07C237/26 C07C2603/46

    摘要: The present invention relates to crystalline form C of Tigecycline dihydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline form C of Tigecycline dihydrochloride as an intermediate for the preparation of an anti-infective medicament. Moreover the present invention relates to pharmaceutical compositions comprising crystalline form C of Tigecycline dihydrochloride in an effective amount and to the use of crystalline form C of Tigecycline dihydrochloride as an anti-infective medicament.

    摘要翻译: 本发明涉及替加环素二盐酸盐的结晶形式C及其制备方法。 此外,本发明涉及替加环素二盐酸盐的结晶形式C作为制备抗感染药物的中间体的用途。 此外,本发明涉及有效量的包含替加环素二盐酸盐的结晶形式C的药物组合物和使用替加环素二盐酸盐的结晶形式C作为抗感染药物。

    Crystalline form C of tigecycline dihydrochloride and methods for its preparation
    5.
    发明授权
    Crystalline form C of tigecycline dihydrochloride and methods for its preparation 有权
    替加环素二盐酸盐的结晶形式C及其制备方法

    公开(公告)号:US08513224B2

    公开(公告)日:2013-08-20

    申请号:US13133164

    申请日:2009-12-18

    CPC分类号: C07C237/26 C07C2603/46

    摘要: The present invention relates to crystalline form C of Tigecycline dihydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline form C of Tigecycline dihydrochloride as an intermediate for the preparation of an anti-infective medicament. Moreover the present invention relates to pharmaceutical compositions comprising crystalline form C of Tigecycline dihydrochloride in an effective amount and to the use of crystalline form C of Tigecycline dihydrochloride as an anti-infective medicament.

    摘要翻译: 本发明涉及替加环素二盐酸盐的结晶形式C及其制备方法。 此外,本发明涉及替加环素二盐酸盐的结晶形式C作为制备抗感染药物的中间体的用途。 此外,本发明涉及有效量的包含替加环素二盐酸盐的结晶形式C的药物组合物和使用替加环素二盐酸盐的结晶形式C作为抗感染药物。

    REDUCTION OF ORGANIC COMPOUNDS WITH LOW AMOUNTS OF HYDROGEN
    6.
    发明申请
    REDUCTION OF ORGANIC COMPOUNDS WITH LOW AMOUNTS OF HYDROGEN 审中-公开
    减少氢含量低的有机化合物

    公开(公告)号:US20120232266A1

    公开(公告)日:2012-09-13

    申请号:US13501253

    申请日:2010-11-26

    摘要: The present invention relates to a process for the reaction of a compound with hydrogen wherein the reaction is conducted using a hydrogen-containing gas comprising up to about 10 vol. % hydrogen and at least about 90 vol. % of an inert gas and wherein the compound to be reacted with hydrogen is provided in a liquid phase. The process of the present invention is particularly suitable for hydrogenation and hydrogenolysis reactions.

    摘要翻译: 本发明涉及一种化合物与氢气反应的方法,其中该反应是使用包含至多约10vol。 %氢和至少约90体积%。 %的惰性气体,其中与氢反应的化合物以液相形式提供。 本发明的方法特别适用于氢化和氢解反应。

    ANTIBIOTIC COMPOUNDS
    7.
    发明申请
    ANTIBIOTIC COMPOUNDS 审中-公开
    抗生素化合物

    公开(公告)号:US20110124893A1

    公开(公告)日:2011-05-26

    申请号:US12863654

    申请日:2009-01-19

    IPC分类号: C07C237/26

    摘要: The present invention relates to the new crystalline solid form XI of Tigecycline and a process of preparing the same. Form XI of Tigecycline is particularly suitable for the isolation of Tigecycline in the last step of the synthesis of Tigecycline. Further the present invention relates to a process of preparing amorphous Tigecycline by spray drying form XI or another crystalline form of Tigecycline.

    摘要翻译: 本发明涉及替加环素的新结晶固体XI型及其制备方法。 替加环素的XI型XI特别适用于替加环素合成最后一步中替加环素的分离。 本发明还涉及通过XI型喷雾干燥或替加环素的另一结晶形式制备非晶替加环素的方法。